Actionable insights on equities, fixed-income, macros and personal finance Start 14-Days Free Trial
Actionable investing insights Get Free Trial

Dr. Reddy's Laboratories recalls 84,240 bottles of Acid Controller tablets


DRL LogoDrug major Dr. Reddy’s Laboratories Inc. (the US subsidiary of Dr. Reddy’s), initiated a recall of Acid Controller tablets.

The tablets relieves heartburn associated with acid indigestion and sour stomach and as well prevents heartburn associated with acid indigestion and sour stomach brought on by eating or drinking certain food and beverages.

The recall

An action basically taken to remove the particular product from the market can be done by either the company itself or by the FDA under its own statutory authority. In this case, it is a Voluntary recall initiated by the company itself.

The recall has been initiated in the US alone and has been classified as a Class III recall which means the exposure to this recalled product is not likely to cause adverse health consequences.

The products were labelled and distributed by CVS pharmacy (CVS phCVS Pharmacyarmacy OriginalStrength Acid Controller tablets, 10 mg, 30-count bottle, OTC) . The batches recalled has an expiry date of May, 2017. The recall has been initiated since 22-Apr-16.

Reason for Recall?

While not all details have been divulged by the company or the FDA, the simple reason stated is “Failed impurities/degradation specification: An out of specification results has been determined for an individual related substance during stability testing at the 18th month interval for the Famotidine 10 mg Tablet, USP.”

Capital Mind divider


Nothing in this newsletter is financial advice and should not be construed as such. Please do not take trading decisions based solely on the matter above; if you do, it is entirely at your own risk without any liability to Capital Mind. This is educational or informational matter only, and is provided as an opinion. 

Disclosure: The authors at Capital Mind have positions in the market and some of them may support or contradict the material given above, or may involve a direction derived from independent analysis.


Like our content? Join Capitalmind Premium.

  • Equity, fixed income, macro and personal finance research
  • Model equity and fixed-income portfolios
  • Exclusive apps, tutorials, and member community
Subscribe Now Or start with a free-trial